Colorectal Adenocarcinoma

About
Mappings

NCI Thesaurus: Colorectal Adenocarcinoma (coding:ncit:C5105)

OncoTree: Colorectal Adenocarcinoma (coding:oncotree:COADREAD)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this cancer type.

Organizations
Biomarkers
Cancer types
Therapies
Organizations Biomarkers Cancer types Therapies
FDA (2) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Irinotecan
FDA (2) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
FDA (2) EGFR positive, Wild type KRAS Colorectal Adenocarcinoma Cetuximab
EMA (2) FDA (4) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib
EMA (4) FDA (4) MSI-H Colorectal Adenocarcinoma Ipilimumab, Nivolumab
FDA (2) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
FDA (2) Wild type HRAS, Wild type KRAS Colorectal Adenocarcinoma Panitumumab
EMA (1) FDA (2) dMMR Colorectal Adenocarcinoma Pembrolizumab
EMA (1) FDA (2) MSI-H Colorectal Adenocarcinoma Pembrolizumab
FDA (2) KRAS p.G12C Colorectal Adenocarcinoma Adagrasib, Cetuximab
EMA (4) FDA (4) dMMR Colorectal Adenocarcinoma Ipilimumab, Nivolumab
FDA (2) MSI-H Colorectal Adenocarcinoma Nivolumab
FDA (2) dMMR Colorectal Adenocarcinoma Nivolumab
EMA (2) FDA (2) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Oxaliplatin
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Irinotecan
EMA (1) EGFR positive, Wild type HRAS, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Cetuximab, Fluorouracil, Oxaliplatin
EMA (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Oxaliplatin, Panitumumab
EMA (2) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Fluorouracil, Irinotecan, Panitumumab
EMA (1) Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Panitumumab
FDA (2) HER2-positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Trastuzumab, Tucatinib
FDA (2) BRAF p.V600E Colorectal Adenocarcinoma Cetuximab, Encorafenib, Fluorouracil, Irinotecan